Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | RET |
Variant | D567Y |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | RET D567Y lies within the extracellular domain of the Ret protein (UniProt.org). D567Y results in increased phosphorylation of Ret and Erk, IL3-independent growth in culture, and tumor formation in a mouse model (PMID: 36166639). |
Associated Drug Resistance | |
Category Variants Paths |
RET mutant RET act mut RET D567Y |
Transcript | NM_020975.6 |
gDNA | chr10:g.43112903G>T |
cDNA | c.1699G>T |
Protein | p.D567Y |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_020630.5 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
NM_001406765.1 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
NM_020630.7 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
NM_020975.6 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
NM_001406743.1 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
NM_020975.5 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
NM_001406744.1 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
NM_001406760.1 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
NM_001406759.1 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
NM_001406763.1 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET D567Y | Advanced Solid Tumor | sensitive | Pralsetinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Gavreto (pralsetinib) inhibited Ret signaling and viability in transformed cells expressing RET D567Y in culture and inhibited tumor growth in a cell line xenograft model (PMID: 36166639). | 36166639 |
RET D567Y | Advanced Solid Tumor | sensitive | Selpercatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Retevmo (selpercatinib) inhibited Ret signaling and viability in transformed cells expressing RET D567Y in culture and inhibited tumor growth in a cell line xenograft model (PMID: 36166639). | 36166639 |